Blue Earth Diagnostics Announces Results from Initial Clinical Experience of 18F-rhPSMA-7 PET Imaging by Technical University of Munich (1)

Published 07 May 2019

Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced results from early clinical experience in Germany with positron emission tomography/computed tomography (PET/CT) imaging using a lead radiohybrid Prostate Specific Membrane Antigen-targeted compound (18F-rhPSMA-7) by the Technical University of Munich (TUM) in two presentations at AUA2019. Blue Earth Diagnostics acquired exclusive rights to a broad family of rhPSMA agents in 2018.

  • In an oral presentation, results of a retrospective analysis of 58 patients with high risk primary prostate cancer indicated that 18F-rhPSMA-7 PET/CT demonstrated sensitivity of 72% (13/18), specificity of 93% (37/40) and diagnostic accuracy 86% (50/58), when compared to histopathological findings.
  • A poster presentation described results from another retrospective analysis of 261 patients with biochemically recurrent prostate cancer in which 18F-rhPSMA-7 PET/CT demonstrated a detection rate of 81% (211/261) at a median PSA level of 0.96 ng/mL.

These retrospective analyses were presented at the American Urological Association’s 2019 Annual Meeting, AUA2019, May 3-6, 2019 in Chicago, Ill.

NOTE: this early clinical experience with 18F-rhPSMA-7 by TUM in Germany, consistent with the German Medicinal Products Act 13 (2b), reflects use of an investigational agent for which safety and efficacy have not been established by the U.S. Food and Drug Administration.

“We are very pleased that TUM is able to share the results of this initial clinical experience with the prestigious urology community at AUA2019,” said Jonathan Allis, D. Phil., CEO of Blue Earth Diagnostics. “Blue Earth Diagnostics acquired rhPSMA last year as part of our mission to develop and commercialize innovative PET imaging agents for cancer. rhPSMA is a strategic expansion of our technologically advanced imaging portfolio, and a complement to approved, commercially available Axumin® (fluciclovine F 18). We believe that both agents may ultimately provide physicians and their patients living with recurrent prostate cancer the ability to select the diagnostic agent most appropriate to each specific clinical situation. We are currently progressing development of a lead 18F-rhPSMA imaging candidate and collaborating with Scintomics to identify optimized therapeutic candidates for future development.”

“Effective staging of primary prostate cancer and determining the extent and location of recurrent disease are important elements in determining appropriate management of these patients,” said Tobias Maurer, MD, of the Martini-Klinik and Department of Urology, University of Hamburg-Eppendorf, Germany (previously in the Department of Urology at TUM), who presented the results at AUA2019. “The retrospective analyses of 18F-rhPSMA-7 PET/CT demonstrated an accuracy of 86% (50/58) in men with primary prostate cancer and a detection rate of 81% (211/261) in men with biochemical recurrence, at a median PSA level of 0.96 ng/mL. These preliminary data are encouraging and support further research with rhPSMA.”

“The TUM initial experience with 18F-rhPSMA-7 has allowed us to investigate the potential diagnostic performance of a new class of theranostic PSMA-targeting agents that enable efficient labelling with imaging radioisotopes such as 18F for PET imaging or 177Lu for therapeutic use,” said Matthias Eiber, MD, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM. “PSMA-targeted imaging agents labeled with 18F offer the advantages of broad availability, based on the radioisotope’s half-life; consistent, centralized manufacturing and high resolution PET scans, all of which are important considerations in detecting and localizing prostate cancer.”

About the TUM 18F-rhPSMA-7 PET/CT Presentations at AUA2019

Diagnostic efficacy of 18F-rhPSMA-7 positron emission tomography for lymph node staging in patients with high risk primary prostate cancer

The oral presentation detailed a 58-patient retrospective analysis investigating the efficacy of 18F-rhPSMA-7 PET/CT for primary lymph node staging of prostate cancer compared with conventional imaging and histopathology. Patient-based analysis indicated that the sensitivity, specificity and accuracy of 18F-rhPSMA-7 PET/CT were 72.2% (13/18), 92.5% (37/40) and 86.2% (50/58), respectively. Those for morphological imaging were 50.0% (9/18), 72.5% (29/40) and 65.5% (38/58), respectively. On template-based analysis, the sensitivity, specificity and accuracy of 18F-rhPSMA-7 PET/CT were 51.9% (28/54), 96.6% (311/321) and 91.4% (339/371), respectively and those for morphological imaging were 11.1% (6/54), 95.3% (306/321) and 84.1% (312/371), respectively. The mean PSA level in the primary prostate cancer study was 12.4 ng/mL.

18F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy

The poster presentation described results from a retrospective dataset analysis of 261 patients with non-castrate biochemical recurrence after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT imaging. The detection rate of presumed recurrence sites was correlated with patients’ PSA level, primary Gleason score and prior therapy. Results demonstrated that 211 patients (80.8%) (211/261) showed pathological findings on 18F-rhPSMA-7 PET/CT. Detection rates were 71.2% (42/59) at PSA levels of 0.2 to <0.5 ng/mL; 86.3% (44/51) at PSA levels of 0.5 to <1 ng/mL; 85.7% (42/49) at PSA levels of 1 to <2 ng/mL and 95.0% (76/80) at PSA levels ≥ 2ng/mL. 18F-rhPSMA-7 PET/CT revealed local recurrence in 43.3% (113) patients. Lymph node metastases were present in the pelvis in 42.2% (110), in the retroperitoneum in 17.2% (45) and in the supradiaphragmatic location in 8.0% (21) patients. Bone and visceral metastases were detected in 20.7% (54) and 3.8% (10) patients, respectively. In 31.8% (7/22) patients with a PSA < 0.2 ng/ml, suspicious lesions were present. Detection efficacy was not influenced by prior external beam radiation therapy (EBRT) (79.1% vs. 82.1%; p = 0.55), androgen deprivation therapy (ADT) within the 6 months preceding imaging (80.6% vs. 80.9%; p = 0.54) or by primary Gleason score (77.9% for Gleason Score ≤ 7 vs. 82.6% for Gleason Score ≥ 8; p = 0.38).


About rhPSMA

Blue Earth Diagnostics acquired exclusive, worldwide rights to radiohybrid Prostate Specific Membrane Antigen (PSMA)-targeted technology (rhPSMA) from Scintomics in 2018. rhPSMA originated from the Chair of Pharmaceutic Radiochemistry at the Technical University of Munich, Germany, by Alexander Wurzer and Hans Juergen Wester, and has been utilized clinically under German legislation at the Department of Nuclear Medicine for the diagnostic imaging of men with both primary and recurrent prostate cancer. 18F-rhPSMA consists of a prostate-specific membrane antigen (PSMA) receptor ligand, which attaches to and is internalized by prostate cancer cells, and is labeled with the 18F radioisotope for PET imaging. rhPSMA compounds can also be labeled with radioisotopes such as 177Lu and 225Ac for therapeutic use. 18F-rhPSMA, 177Lu-rhPSMA and 225Ac-rhPSMA have not received regulatory approval.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations about 18F-rhPSMA-7 discuss experiences with an investigational agent for which the safety and efficacy have not been established by the FDA.

This press release is intended to provide information about Blue Earth Diagnostics’ business in the United States and Europe. Please be aware that the approval status and product label for Axumin varies by country worldwide. For EU Axumin product information refer to:

U.S. Indication and Important Safety Information About Axumin



Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.


  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
  • Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
  • Adverse reactions were reported in ≤ 1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or


Full U.S. Axumin prescribing information is available at

About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. The company’s pipeline includes Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit:



For Blue Earth Diagnostics (U.S.)                                          Media  

Priscilla Harlan                                                                          Sam Brown Inc.

Vice President, Corporate Communications                       Mike Beyer

(M) (781) 799-7917                                                                  (M) (312) 961-2502                                                            

For Blue Earth Diagnostics (UK)

Georgina Mowatt

Communications Manager

Tel: +44 (0) 7810 355 912

#            #            #

Syncona Limited Disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);


  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.


Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No Warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability Waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy Policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked Sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing Law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.